Search results
Results from the WOW.Com Content Network
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. [6]
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
Efalizumab (brand name Raptiva, Genentech, Merck Serono) is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis.As implied by the suffix -zumab, it is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection.
Genentech's Obinutuzumab (GA101) Significantly Reduced the Risk of Disease Progression or Death in People with One of the Most Common Forms of Blood Cancer Phase III data from the CLL11 study to ...
Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCO -- First Phase III Data on Obinutuzumab (GA101) in one of the Most Commonly Diagnosed Blood Cancers -- -- Early ...
Genentech previously said the use of the drug in the indication accounts for a fraction of its overall revenue. The U.S. Food and Drug Administration had granted accelerated approval to Gavreto in ...
Emicizumab, sold under the brand name Hemlibra, is a humanized bispecific monoclonal antibody for the treatment of haemophilia A, developed by Genentech and Chugai (both organizations are subsidiaries of Hoffmann-La Roche). [4] A Phase I clinical trial found that it was well tolerated by healthy subjects. [5]
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab.It is an anti-angiogenic [16] that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.